Ireland - English - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - cyclophosphamide monohydrate - coated tablet - 50 milligram(s) - nitrogen mustard analogues; cyclophosphamide

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - cyclophosphamide - coated tablet - cyclophosphamide 50 mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - cyclophosphamide monohydrate - coated tablets - 50 milligram - cyclophosphamide

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

baxter healthcare south africa (pty) ltd - tablet - see ingredients - each tablet contains cyclophosphamide 50,0 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

baxter oncology, germany - cyclophosphamide - film-coated tablet - 50 mg

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - cyclophosphamide - coated tablet - cyclophosphamide 50 mg - antineoplastic agents

Singapore - English - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - cyclophosphamide - tablet, sugar coated - 50 mg - cyclophosphamide 50 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - cyclophosphamide -

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - cyclophosphamide monohydrate, quantity: 1.069 g (equivalent: cyclophosphamide monohydrate, qty 1 g) - injection, powder for - excipient ingredients: - frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter's staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease). *modified as the international staging classification for hodgkin's disease in 'report of the committee on the staging of hodgkin's disease'. cancer res 26: 1310, 1966. stage i. disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm. stage ii. disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm. stage iii. disease on both sides of the diaphragm but not extending beyond the involvement of lymph nodes, spleen and/or waldeyer's ring. stage iv. involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer's ring. all stage

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - cyclophosphamide monohydrate, quantity: 534.5 mg (equivalent: cyclophosphamide monohydrate, qty 500 mg) - injection, powder for - excipient ingredients: - frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter's staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease). *modified as the international staging classification for hodgkin's disease in 'report of the committee on the staging of hodgkin's disease'. cancer res 26: 1310, 1966. stage i. disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm. stage ii. disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm. stage iii. disease on both sides of the diaphragm but not extending beyond the involvement of lymph nodes, spleen and/or waldeyer's ring. stage iv. involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer's ring. all stage